VivoSeq
Cardiovascular

Chronic Thromboembolic Pulmonary Hypertension

10

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Chronic Thromboembolic Pulmonary Hypertension is an early-stage landscape with 10 programs across 6 companies. The most active players are Johnson & Johnson, Gilead, United Therapeutics. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

0/100

Mech. Concentration

60/100

Completion Rate

71/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

3 programs

Phase 3Gilead logo

Gilead

1 program

Phase 3United Therapeutics logo

United Therapeutics

1 program

Phase 3Bayer logo

Bayer

3 programs

Phase 3Pfizer logo

Pfizer

1 program

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

22

clinical trials

Completed12 · 55%
Terminated5 · 23%
Recruiting3 · 14%
No longer available1 · 5%
Unknown status1 · 5%

Clinical Trials

Trial Activity

22 trials

Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension
Recruiting·—·N/A·NCT05340023·120 enrolled
Registry of Patients With chrOnic thromboemboLic Pulmonary hypErTension
Recruiting·—·N/A·NCT07254078·500 enrolled
Evaluation of Frailty, Physical Capacity and Lung Function in Postoperative Pulmonary Endarterectomy Patients: an Observational and Prospective Clinical Study
Recruiting·UUniversity of Sao Paulo General Hospital·N/A·NCT06286891·50 enrolled
Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT00313222·157 enrolled
Sleep-Disordered Breathing in Chronic Thromboembolic Pulmonary Hypertension
Completed·MMedical University of Vienna·N/A·NCT03074539·50 enrolled
Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT00319111·151 enrolled
Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT02021292·80 enrolled
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )
Completed·Bayer logoBayer·N/A·NCT02117791·1,298 enrolled
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
Completed·Bayer logoBayer·N/A·NCT02545465·125 enrolled
Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension
Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02634203·105 enrolled
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Completed·Bayer logoBayer·Phase 3·NCT00910429·237 enrolled
This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Completed·Bayer logoBayer·Phase 1·NCT03754660·38 enrolled
Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)
Completed·SSciPharm SàRL·Phase 3·NCT01416636·105 enrolled
Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT02060721·76 enrolled
Initial Dual Oral Combination Therapy Versus Standard-of-care Initial Oral Monotherapy Prior to Balloon Pulmonary Angioplasty in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT04780932·96 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)